MedNews: Retension Pharmaceuticals raises $10.4 million to fund clinical trials for patients suffering from resistant and uncontrolled hypertension
Retension Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing RTN-001 as a therapy for patients with hypertension.